Pharmacogenetic Approach for the Prevention of Rivaroxaban’s ADRs: A Systematic Review and Meta-Analysis

Pharmacogenetic Approach for the Prevention of Rivaroxaban’s ADRs: A Systematic Review and Meta-Analysis

Introduction. Pharmacogenetics is a potential approach that can be applied to decline the burden of rivaroxaban’s ADRs. The current systematic review and meta-analysis aim to identify genetic variants correlated with rivaroxaban exposure and evaluate their importance. Methods. We systematically sear...

Full description

Bibliographic Details
Main Authors:	Parham Mardi, Bahareh Abbasi, Arman Shafiee, Tara Afsharmoghaddam
Format:	Article
Language:	English
Published:	Hindawi - Cambridge University Press 2023-01-01
Series:	Genetics Research
Online Access:	http://dx.doi.org/10.1155/2023/6105320

Similar Items

A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
by: Ali Mohammed Abd Alridha, et al.
Published: (2022-01-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

Opium abuse and stroke in Iran: A systematic review and meta-analysis
by: Parham Mardi
Published: (2022-09-01)

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series
by: Livija Šimičević, et al.
Published: (2023-02-01)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
by: Can Chen, et al.
Published: (2021-02-01)

Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
by: Alberto Guijosa, et al.
Published: (2022-10-01)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
by: Zhuang Liu, et al.
Published: (2023-04-01)

Adres łaciński
by: Jerzy A. Wojtczak-Szyszkowski
Published: (2023-09-01)

A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease
by: Maria Tziastoudi, et al.
Published: (2021-04-01)

Rivaroxaban: Drug review
by: Abhishek Kumar Singh, et al.
Published: (2020-01-01)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
by: A T Cohen, et al.
Published: (2016-01-01)

The ADR Market and the Effects of ADR Issue on the Underlying Security; a Survey
by: Franco Parisi
Published: (1996-03-01)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023-02-01)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
by: Ikhwan Rinaldi, et al.
Published: (2022-07-01)

Consumer ADR in Europe
by: Hodges, C
Published: (2012)

ADR principles and practice /
by: 369991 Brown, Henry J., et al.
Published: (1999)

Impact of pharmacogenetics on aspirin resistance: a systematic review
by: Gustavo Figueiredo da Silva, et al.
Published: (2023-01-01)

Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review
by: Johanna Raymond, et al.
Published: (2021-01-01)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
by: A T Cohen, et al.
Published: (2016-01-01)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
by: A T Cohen, et al.
Published: (2015-01-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
by: Rupert Bauersachs, et al.
Published: (2020-05-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014-03-01)

Is non-high-density lipoprotein associated with metabolic syndrome? A systematic review and meta-analysis
by: Parham Mardi, et al.
Published: (2022-09-01)

Impact of incentives on COVID-19 vaccination; A systematic review
by: Parham Mardi, et al.
Published: (2022-09-01)

Consumer-to-business ADR structures
by: Hodges, C, et al.
Published: (2012)

Market segmentation: Venezuelan ADRs
by: Urbi Garay, et al.
Published: (2012-12-01)

A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
by: Nathan R. Hill D.Phil, et al.
Published: (2020-01-01)

Analysis of Chinese Market Average Daily Rate (ADR) to Overall ADR at Conrad Bali Hotel
by: Ni Kadek Sri Jayanti, et al.
Published: (2020-09-01)

The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis
by: Yuxin Teng, et al.
Published: (2023-03-01)

Update on Rivaroxaban
by: Osama Moussa, et al.
Published: (2010-01-01)

Rivaroxaban in secondary prevention of cardioembolic stroke: standards and abnormal situations
by: A.V. Fonyakin, et al.
Published: (2014-05-01)

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
by: M Stevenson, et al.
Published: (2009-10-01)

Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan
by: Yun-Chuan Mao, et al.
Published: (2015-10-01)

Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis
by: Zhenzhen Yang, et al.
Published: (2023-02-01)

The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review
by: Yalçin N, et al.
Published: (2022-06-01)

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis
by: Arman Shafiee, et al.
Published: (2023-06-01)

Brain‐derived neurotrophic factor (BDNF) levels in panic disorder: A systematic review and meta‐analysis
by: Arman Shafiee, et al.
Published: (2024-01-01)